These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

127 related articles for article (PubMed ID: 8380330)

  • 41. DNA topoisomerases I & II cleavage sites in the type 1 human immunodeficiency virus (HIV-1) DNA promoter region.
    Pommier Y; Poddevin B; Gupta M; Jenkins J
    Biochem Biophys Res Commun; 1994 Dec; 205(3):1601-9. PubMed ID: 7811242
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Analysis of topoisomerase II-mediated DNA cleavage of the c-myc gene during HL60 differentiation.
    Riou JF; Gabillot M; Riou G
    FEBS Lett; 1993 Nov; 334(3):369-72. PubMed ID: 8243649
    [TBL] [Abstract][Full Text] [Related]  

  • 43. In vivo stimulation by antitumor drugs of the topoisomerase II induced cleavage sites in c-myc protooncogene.
    Riou JF; Multon E; Vilarem MJ; Larsen CJ; Riou G
    Biochem Biophys Res Commun; 1986 May; 137(1):154-60. PubMed ID: 3013177
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Application of a degenerate consensus sequence to quantify recognition sites by vertebrate DNA topoisomerase II.
    Spitzner JR; Muller MT
    J Mol Recognit; 1989 Sep; 2(2):63-74. PubMed ID: 2561527
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Expression of a mutant DNA topoisomerase II in CCRF-CEM human leukemic cells selected for resistance to teniposide.
    Bugg BY; Danks MK; Beck WT; Suttle DP
    Proc Natl Acad Sci U S A; 1991 Sep; 88(17):7654-8. PubMed ID: 1652758
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Uncoupling the DNA cleavage and religation activities of topoisomerase II with a single-stranded nucleic acid substrate: evidence for an active enzyme-cleaved DNA intermediate.
    Gale KC; Osheroff N
    Biochemistry; 1990 Oct; 29(41):9538-45. PubMed ID: 2176849
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Sequence selectivity of topoisomerase II DNA cleavage stimulated by mitoxantrone derivatives: relationships to drug DNA binding and cellular effects.
    De Isabella P; Capranico G; Palumbo M; Sissi C; Krapcho AP; Zunino F
    Mol Pharmacol; 1993 May; 43(5):715-21. PubMed ID: 8388987
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Two independent amsacrine-resistant human myeloid leukemia cell lines share an identical point mutation in the 170 kDa form of human topoisomerase II.
    Lee MS; Wang JC; Beran M
    J Mol Biol; 1992 Feb; 223(4):837-43. PubMed ID: 1311390
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Analysis of yeast DNA topoisomerase II mutants resistant to the antitumor drug amsacrine.
    Wasserman RA; Wang JC
    Cancer Res; 1994 Apr; 54(7):1795-800. PubMed ID: 8137294
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Mutational analysis of a type II topoisomerase cleavage site: distinct requirements for enzyme and inhibitors.
    Freudenreich CH; Kreuzer KN
    EMBO J; 1993 May; 12(5):2085-97. PubMed ID: 8387918
    [TBL] [Abstract][Full Text] [Related]  

  • 51. mAMSA resistant human topoisomerase IIbeta mutation G465D has reduced ATP hydrolysis activity.
    Gilroy KL; Leontiou C; Padget K; Lakey JH; Austin CA
    Nucleic Acids Res; 2006; 34(5):1597-607. PubMed ID: 16549872
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Decreased nuclear matrix DNA topoisomerase II in human leukemia cells resistant to VM-26 and m-AMSA.
    Fernandes DJ; Danks MK; Beck WT
    Biochemistry; 1990 May; 29(17):4235-41. PubMed ID: 2163274
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Enhanced amsacrine-induced mutagenesis in plateau-phase Chinese hamster ovary cells, with targeting of +1 frameshifts to free 3' ends of topoisomerase II cleavable complexes.
    Patteson K; Wang P; Povirk LF
    Cancer Res; 1999 Aug; 59(15):3682-8. PubMed ID: 10446982
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Topoisomerase I and II cleavage of adenovirus DNA in vivo: both topoisomerase activities appear to be required for adenovirus DNA replication.
    Schaack J; Schedl P; Shenk T
    J Virol; 1990 Jan; 64(1):78-85. PubMed ID: 2152835
    [TBL] [Abstract][Full Text] [Related]  

  • 55. A study of drug-induced topoisomerase II-mediated DNA lesions on episomal chromatin.
    Cullinan EB; Beerman TA
    J Biol Chem; 1989 Sep; 264(27):16268-75. PubMed ID: 2550434
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Small deletion and insertion mutations induced by the topoisomerase II inhibitor teniposide in CHO cells and comparison with sites of drug-stimulated DNA cleavage in vitro.
    Han YH; Austin MJ; Pommier Y; Povirk LF
    J Mol Biol; 1993 Jan; 229(1):52-66. PubMed ID: 8380617
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Identification within the simian virus 40 genome of a chromosomal loop attachment site that contains topoisomerase II cleavage sites.
    Pommier Y; Cockerill PN; Kohn KW; Garrard WT
    J Virol; 1990 Jan; 64(1):419-23. PubMed ID: 2152827
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Position-specific effect of ribonucleotides on the cleavage activity of human topoisomerase II.
    Wang Y; Thyssen A; Westergaard O; Andersen AH
    Nucleic Acids Res; 2000 Dec; 28(24):4815-21. PubMed ID: 11121471
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Reduced DNA break formation and cytotoxicity of the topoisomerase II drug 4'-(9'-acridinylamino)methanesulfon-m-anisidide when combined with hyperthermia in human and rodent cell lines.
    Kampinga HH; van den Kruk G; Konings AW
    Cancer Res; 1989 Apr; 49(7):1712-7. PubMed ID: 2538233
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Minimal DNA requirement for topoisomerase II-mediated cleavage in vitro.
    Lund K; Andersen AH; Christiansen K; Svejstrup JQ; Westergaard O
    J Biol Chem; 1990 Aug; 265(23):13856-63. PubMed ID: 2166042
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.